Table 1: Comparing
demographic and clinical profile of patients treated with Combined
dose Aliskiren and Losartan, Aliskiren alone and Losartan alone (Year 1 to 6).
|
|
Aliskiren
n = 52 |
Losartan n = 51 |
Combined aliskiren
and losartan n = 51 |
p value |
|
Sex
(F : M) |
36:16 |
30:21 |
32:19 |
0.540 |
|
Count
(%) |
69%:31% |
59%:41% |
63%:37% |
|
|
Age
at Diagnosis (Years) |
52
± 11 |
54 ± 12 |
52 ± 9 |
0.348 |
|
Duration
of Trial (Months) |
37
± 2 |
38
± 2 |
37
± 3 |
0.677 |
|
Comorbidities,
Count (%) |
||||
|
Hypertension
|
20 (39%) |
29 (57%) |
23 (45%) |
0.166 |
|
Hypercholesterolaemia |
22 (42%) |
34 (67%) |
25 (49%) |
0.038 |
|
IHD |
6
(12%) |
7
(14%) |
10
(20%) |
0.495 |
|
EGFR (ml/min) |
||||
|
Year 0 |
47 ± 13 |
49 ± 14 |
48 ± 12 |
0.769 |
|
Year 6 |
41 ± 14 |
46 ± 18 |
45 ± 15 |
0.189 |
|
|
(p < 0.001) |
(p = 0.001) |
(p
= 0.012) |
|
|
Urinary
Protein (gm/day) |
||||
|
Year
0 |
1.4
± 0.7 |
1.3
± 0.6 |
1.2
± 0.7 |
0.316 |
|
Year
6 |
0.6
± 0.6 |
0.3
± 0.3 |
0.4
± 0.4 |
0.758 |
|
|
(p
< 0.001) |
(p
< 0.001) |
(p
< 0.001) |
|
|
Blood
Pressure (mmHg) |
||||
|
Systolic,
Year 0 |
138
± 10 |
133
± 14 |
134
± 11 |
0.071 |
|
Systolic,
Year 6 |
129
± 9 |
130
± 9 |
130
± 10 |
0.758 |
|
|
(p
< 0.001) |
(p
= 0.253) |
(p
< 0.086) |
|
|
Diastolic,
Year 0 |
86
± 7 |
85
± 8 |
86
± 7 |
0.676 |
|
Diastolic,
Year 6 |
82
± 5 |
82
± 5 |
80
± 6 |
0.304 |
|
|
(p
< 0.001) |
(p
= 0.044) |
(p
< 0.001) |
|
|
Improvement in eGFR |
15
(29%) |
15
(29%) |
17
(33%) |
0.866 |
|
Response:
Year 4 to 6 |
||||
|
Remission
”x” |
15
(29%) |
12
(23%) |
16
(31%) |
0.043 |
|
Relapse
“y” |
15
(29%) |
9
(18%) |
20
(39%) |
|
|
Continuing
Proteinuria “z” |
22
(42%) |
30
(59%) |
15
(30%) |
|
Continuous data are presented as mean ± SD and
categorical data as count (%).